Obesity, a major risk factor for the development of diabetes mellitus, cardiovascular diseases
and certain types of cancer, arises from a chronic positive energy balance that is often due to …

Background The gastrointestinal peptide hormone ghrelin was discovered in 1999 as the
endogenous ligand of the growth hormone secretagogue receptor. Increasing evidence …

The gut-brain axis, which is mediated via enteric and central neurohormonal signaling, is
known to regulate a broad set of physiological functions from feeding to emotional behavior …

Background: Limb muscle dysfunction is prevalent in chronic obstructive pulmonary disease
(COPD) and it has important clinical implications, such as reduced exercise tolerance …

Cancer cachexia syndrome is a major cause of morbidity and mortality in cancer patients in
the advanced stage. It is a devastating disorder characterized by nutritional impairment …

Cancer cachexia is a metabolic syndrome that can be present even in the absence of weight
loss ('precachexia'). Cachexia is often compounded by pre-existing muscle loss, and is …

Cancer cachexia is a multi-factorial syndrome, which negatively affects quality of life,
responsiveness to chemotherapy, and survival in advanced cancer patients. Our …

Up to 50% of cancer patients suffer from a progressive atrophy of adipose tissue and
skeletal muscle, called cachexia, resulting in weight loss, a reduced quality of life, and a …

Small synthetic molecules called growth hormone secretagogues (GHSs) stimulate the
release of growth hormone (GH) from the pituitary. They act through the GHS-R, a G protein …

BACKGROUND Cachexia, described as weight loss (mainly in lean body mass [LBM]) and
anorexia, is common in patients with advanced cancer. This study examined the efficacy and …